HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia.
about
Antenatal interventions for fetomaternal alloimmune thrombocytopeniaAntenatal interventions for fetomaternal alloimmune thrombocytopeniaFetal/Neonatal Alloimmune Thrombocytopenia: Pathogenesis, Diagnostics and PreventionDeveloping recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention.Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads.Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions.A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry.How I manage neonatal thrombocytopenia.Usefulness of maternal anti-HPA-1a antibody quantitation in predicting severity of foetomaternal alloimmune thrombocytopenia.Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia.Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia.Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies.Expression of a single-chain human leukocyte antigen-DRA/DRB3*01:01 molecule and differential binding of a monoclonal antibody in the presence of specifically bound human platelet antigen-1a peptide.
P2860
Q24234535-FDC57B85-80AD-4156-A7D3-5BC5FA366481Q24245104-761108FF-F36B-4592-B9F3-64E37A77F5ACQ26777281-2C7B118C-B036-40DE-9EDA-873CDACA11EEQ33380492-1631F35F-4EF5-4D1C-A24E-39923CDED547Q33392862-CA3184A3-D005-42B9-9F9D-3F2F946ECFABQ33393340-F2657E55-62F8-481E-AC58-355FB8EF1014Q33395535-E63B3978-C8B1-4A70-9420-7018496AEA94Q33395614-744B62ED-3B83-490D-B210-8BF99CE60689Q33397361-FDBB8AA4-6BA8-41E1-8A27-A4A56972DAAEQ33406141-18932E1E-5B25-443E-BB40-96561C709E4BQ33407495-3C943A3A-7F1A-4374-835C-1A8DD8FF7AECQ33431066-5C0D77FF-ED46-436D-95CF-4E8547AE1CF4Q33441520-6B1A98AE-5F7F-45C1-B122-48674480890EQ33442939-728C3941-CA9B-49D1-A824-0E7F43AB324BQ54486514-7F69AA80-8A20-464B-BED7-CBD2950D1A3C
P2860
HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@ast
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@en
type
label
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@ast
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@en
prefLabel
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@ast
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@en
P2093
P2860
P50
P1433
P1476
HPA-1a antibody potency and bi ...... l alloimmune thrombocytopenia.
@en
P2093
Cedric Ghevaert
Dave Allen
Edmund Ranasinghe
Graham A Smith
Kate Campbell
Lorna M Williamson
Paul Metcalfe
P2860
P304
P356
10.1111/J.1537-2995.2007.01273.X
P577
2007-07-01T00:00:00Z